comparemela.com

Latest Breaking News On - Amarin chart - Page 1 : comparemela.com

Amarin Applauds HealthyWomen s Citizen s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event Seite 1

24.04.2024 - Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect PatientsDUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) - . Seite 1

Nabil abadirChief medical officerAmarin chartMarin kursMarin aktie

New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

06.04.2024 - - Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels - - Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) – DUBLIN, . Seite 1

Nabil abadirJournal of the american college cardiologyHead of global medical affairsAmarin corporationMajor adverse cardiovascular eventsAmerican collegeChief medical officerGlobal medical affairsAmarin chartMarin kursMarin aktie

Research Evaluating Benefits of VASCEPA/VAZKEPA (icosapent ethyl) to be Presented at the American College of Cardiology s (ACC) Annual Scientific Session & Expo Seite 1

25.03.2024 - - Subgroup Analyses from REDUCE-IT and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting - DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) - Amarin Corporation plc (NASDAQ:AMRN) . Seite 1

Michael millerElliota brintonNabil abadirDeepakl bhattHead of global medical affairs at amarinChief medical officerGlobal medical affairsAvailable aprilModerated poster theaterAmarin chartMarin kursMarin aktie

vimarsana © 2020. All Rights Reserved.